169 related articles for article (PubMed ID: 27904474)
1. Poly(ADP-ribose) polymerase inhibition reveals a potential mechanism to promote neuroprotection and treat neuropathic pain.
Komirishetty P; Areti A; Gogoi R; Sistla R; Kumar A
Neural Regen Res; 2016 Oct; 11(10):1545-1548. PubMed ID: 27904474
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy.
Komirishetty P; Areti A; Gogoi R; Sistla R; Kumar A
Neuropharmacology; 2017 Feb; 113(Pt A):137-147. PubMed ID: 27712995
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy.
Komirishetty P; Areti A; Yerra VG; Ruby PK; Sharma SS; Gogoi R; Sistla R; Kumar A
Life Sci; 2016 Apr; 150():50-60. PubMed ID: 26921631
[TBL] [Abstract][Full Text] [Related]
5. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
Islam BU; Habib S; Ali SA; Moinuddin ; Ali A
Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620
[TBL] [Abstract][Full Text] [Related]
6. Morin Mitigates Chronic Constriction Injury (CCI)-Induced Peripheral Neuropathy by Inhibiting Oxidative Stress Induced PARP Over-Activation and Neuroinflammation.
Komirishetty P; Areti A; Sistla R; Kumar A
Neurochem Res; 2016 Aug; 41(8):2029-42. PubMed ID: 27084773
[TBL] [Abstract][Full Text] [Related]
7. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Singh N; Sharma G; Singh N; Hanif K
Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
[TBL] [Abstract][Full Text] [Related]
9. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide.
Hortobágyi T; Görlach C; Benyó Z; Lacza Z; Hortobágyi S; Wahl M; Harkany T
Neuroscience; 2003; 121(4):983-90. PubMed ID: 14580948
[TBL] [Abstract][Full Text] [Related]
11. The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Kauppinen TM; Swanson RA
Neuroscience; 2007 Apr; 145(4):1267-72. PubMed ID: 17084037
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Skaper SD
Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
[TBL] [Abstract][Full Text] [Related]
13. Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance.
Gerace E; Scartabelli T; Formentini L; Landucci E; Moroni F; Chiarugi A; Pellegrini-Giampietro DE
Eur J Neurosci; 2012 Jul; 36(1):1993-2005. PubMed ID: 22639866
[TBL] [Abstract][Full Text] [Related]
14. Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets.
Genovese T; Cuzzocrea S
Curr Med Chem; 2008; 15(5):477-87. PubMed ID: 18289003
[TBL] [Abstract][Full Text] [Related]
15. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
Obrosova IG; Li F; Abatan OI; Forsell MA; Komjáti K; Pacher P; Szabó C; Stevens MJ
Diabetes; 2004 Mar; 53(3):711-20. PubMed ID: 14988256
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Kiss L; Szabó C
Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():29-37. PubMed ID: 15962096
[TBL] [Abstract][Full Text] [Related]
18. Docosahexaenoic acid and tetracyclines as promising neuroprotective compounds with poly(ADP-ribose) polymerase inhibitory activities for oxidative/genotoxic stress treatment.
Cieslik M; Pyszko J; Strosznajder JB
Neurochem Int; 2013 Apr; 62(5):626-36. PubMed ID: 23439385
[TBL] [Abstract][Full Text] [Related]
19. Neuronal trauma model: in search of Thanatos.
Cole K; Perez-Polo JR
Int J Dev Neurosci; 2004 Nov; 22(7):485-96. PubMed ID: 15465278
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
